EAM
Erste Asset Management Portfolio holdings
AUM
$11.9B
1-Year Return
22.95%
This Quarter Return
+10.2%
1 Year Return
+22.95%
3 Year Return
+112.82%
5 Year Return
+205.55%
10 Year Return
–
AUM
$4.74B
AUM Growth
+$276M
(+6.2%)
Cap. Flow
-$6.68M
Cap. Flow
% of AUM
-0.14%
Top 10 Holdings %
Top 10 Hldgs %
17.82%
Holding
996
New
57
Increased
184
Reduced
143
Closed
49
Top Buys
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$10.4M |
| 2 |
Kinsale Capital Group
KNSL
|
+$10.1M |
| 3 |
Array Technologies
ARRY
|
+$8.23M |
| 4 |
NVIDIA
NVDA
|
+$7.97M |
| 5 |
Apple
AAPL
|
+$7.32M |
Top Sells
| 1 |
DQ
Daqo New Energy
DQ
|
+$18.4M |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
+$15.7M |
| 3 |
Invesco S&P 500 Equal Weight ETF
RSP
|
+$11.3M |
| 4 |
HEICO
HEI
|
+$10.8M |
| 5 |
SPDR S&P 500 ETF Trust
SPY
|
+$10.4M |
Sector Composition
| 1 | Technology | 28.76% |
| 2 | Healthcare | 20.98% |
| 3 | Consumer Discretionary | 11.7% |
| 4 | Financials | 9.74% |
| 5 | Industrials | 8.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
526
American Financial Group
AFG
$11.5B
| $110K | ﹤0.01% |
800
-2,000
| -71% | -$275K |
|
527
Erasca
ERAS
$457M
| $103K | ﹤0.01% |
25,000
| – | – |
|
528
Nektar Therapeutics
NKTR
$924M
| $103K | ﹤0.01% |
3,120
| – | – |
|
529
Caribou Biosciences
CRBU
$171M
| $84.1K | ﹤0.01% |
13,900
| – | – |
|
530
Fidelity National Financial
FNF
$16.3B
| $83.5K | ﹤0.01% |
2,200
-4,352
| -66% | -$165K |
|
531
iShares Global Energy ETF
IXC
$1.82B
| $82.2K | ﹤0.01% |
2,111
| – | – |
|
532
OmniAb
OABI
$226M
| $81.8K | ﹤0.01% |
+21,070
| New | +$81.8K |
|
|
NSTG
533
DELISTED
NanoString Technologies, Inc.
NSTG
| $78.2K | ﹤0.01% |
9,900
| – | – |
|
534
Kodiak Sciences
KOD
$531M
| $77.6K | ﹤0.01% |
11,300
| – | – |
|
535
Seer Inc
SEER
$114M
| $73.8K | ﹤0.01% |
13,000
| – | – |
|
536
Codexis
CDXS
$221M
| $72.5K | ﹤0.01% |
15,500
| – | – |
|
537
Atara Biotherapeutics
ATRA
$83.9M
| $69.1K | ﹤0.01% |
880
| – | – |
|
538
Boeing
BA
$174B
| $66.1K | ﹤0.01% |
347
| – | – |
|
539
C4 Therapeutics
CCCC
$191M
| $61.6K | ﹤0.01% |
10,700
| – | – |
|
540
Ambev
ABEV
$34.6B
| $59.8K | ﹤0.01% |
22,000
| – | – |
|
541
Verizon
VZ
$184B
| $45.8K | ﹤0.01% |
1,162
-1,677
| -59% | -$66.1K |
|
|
TSVT
542
DELISTED
2seventy bio
TSVT
| $44.8K | ﹤0.01% |
4,999
| – | – |
|
543
Keysight
KEYS
$29.1B
| $44.5K | ﹤0.01% |
260
| – | – |
|
544
Nkarta
NKTX
$147M
| $40.5K | ﹤0.01% |
7,200
| – | – |
|
|
LENZ
545
LENZ Therapeutics
LENZ
$1.14B
| $38.3K | ﹤0.01% |
1,700
| – | – |
|
546
Franco-Nevada
FNV
$37.8B
| $28.7K | ﹤0.01% |
211
| – | – |
|
547
AngloGold Ashanti
AU
$31.3B
| $26.2K | ﹤0.01% |
1,350
| – | – |
|
548
Diamondback Energy
FANG
$39.5B
| $23.3K | ﹤0.01% |
170
| – | – |
|
549
Universal Display
OLED
$6.64B
| $22.1K | ﹤0.01% |
205
-276
| -57% | -$29.8K |
|
550
Tesla
TSLA
$1.12T
| $20.3K | ﹤0.01% |
165
-18,200
| -99% | -$2.24M |
|